-
August 27, 2019Elpiscience Announces Advancement of Two Discovery Molecules into CMC
Shanghai Aug 27th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announces that two key molecules in innate immunity have entered into CMC development stage. ...
-
July 16, 2019Elpiscience: Official Opening of Shanghai R&D Center
On July 16th, 2019, Elpiscience Biopharmaceutical Ltd. (Elpiscience) announced the official opening of its Shanghai R&D Center. In less than two years since its inception, the company has establis...
-
June 28, 2019ES101: First Patient Dosing in Phase I Clinical Trials
On June 28, 2019, Elpiscience Biopharmaceutical Ltd. announced first-patient dosing of first-in-class bispecific antibody ES101, targeting both PD-L1 and 4-1BB, at Shanghai East Hospital. This is...
-
April 25, 2019Elpiscience and Bio-Techne Announce Strategic Collaboration
Shanghai and Minneapolis, April 22, 2019, Elpiscience BioPharma and Bio-Techne Corporation today announced that the companies have entered into a strategic collaboration for the development of an...
-
March 14, 2019Elpiscience to Organize “2019 Shanghai Symposium – Novel Targets for Cancer Immunotherapy”
Shanghai, March 14, 2019, Elpiscience Biopharma, Ltd. announces its first Symposium on “Novel Targets for Cancer Immunotherapy”, which will be held on March 24th, at Shanghai Kempinsk...
-
February 22, 2019Elpiscience Announces Clinical Trial Approval of ES101 in China
Shanghai, February 22, 2019, Elpiscience Biopharma, Ltd. announced today that the bispecific antibody ES101 has been approved by the Center for Drug Evaluation (CDE) for clinical trials in China. ES10...